Dual-indication bet on a bispecific B-cell inhibitor, fully funded to readouts, hinges on whether Phase 2 data justify a crowded HS market entry

Bull

A positive outcome would be statistically significant and clinically meaningful percent reduction from baseline in total abscess and nodule count at Week 16 versus placebo, ideally exceeding or matching the efficacy benchmarks set by approved IL-17 and IL-23 inhibitors. This would validate the B-cell axis as a relevant mechanistic target in HS, differentiate tibulizumab on mechanism, and open partnership or licensing conversations — de-risking the broader dual-indication platform.

Bear

The most likely failure modes are insufficient efficacy on the primary endpoint (percent change in total abscess and nodule count) relative to already-approved agents, potentially reflecting that B-cell inhibition is not a dominant driver of HS pathology in the enrolled population. An adverse safety signal — particularly given the dual BAFF/IL-17A targeting — or a high placebo response rate common in HS trials could also undermine the result, leaving the thesis with no validated indication and a crowded market entry blocked.